PROCEPT BioRobotics Corp (PRCT) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. PROCEPT BioRobotics Corporation is a surgical robotics company focused on urology, specifically treating benign prostatic hyperplasia (BPH) with its AquaBeam and HYDROS robotic systems. As of the reporting date, the company had a global install base of 835 robotic systems, including 653 in the United States.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Revenue | $83.3 million | $58.4 million | $231.7 million | $156.3 million |
| Gross Profit | $54.0 million | $36.9 million | $149.9 million | $93.4 million |
| Gross Margin | 65% | 63% | 65% | 60% |
| Net Loss | $(21.4) million | $(21.0) million | $(65.7) million | $(72.6) million |
| Operating Cash Flow | N/A | N/A | $(38.7) million | $(66.8) million |
| Cash & Equivalents | $294.3 million | N/A | N/A | N/A |
| Long-Term Debt | $51.6 million | N/A | N/A | N/A |
Note: Operating cash flow and cash balances are presented on a Year-to-Date (9-month) basis where applicable, as Q3 specific cash flow data is not explicitly broken out in the summary tables.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 43% year-over-year in Q3 and 48% year-over-year for the nine-month period. Growth was driven by higher sales of robotic systems, handpieces, and service contracts, with U.S. revenue accounting for 89% of Q3 total.
- Margin Expansion: Gross margin improved to 65% in Q3 2025 from 63% in Q3 2024, attributed to increased unit sales spreading fixed manufacturing overhead and higher average selling prices.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 38% in Q3 and 39% YTD, primarily due to commercial expansion and a one-time $3.7 million stock-based compensation charge related to the retirement of the former CEO.
- Debt Restructuring: In August 2025, the company amended its term loan facility. Repayment terms were modified so the entire principal is due at maturity (October 2027) rather than monthly amortization. Additionally, a $2.0 million loan facility liability was paid in full during Q2 2025 after the company met a revenue target.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing cash ($294.3 million) and anticipated revenue are sufficient to fund operations for at least the next 12 months. The company is in compliance with all debt covenants.
- Strategic Focus: The company is focused on growing its install base (targeting ~2,700 U.S. hospitals) and increasing system utilization to drive recurring revenue from consumables.
- Risks: Key risks include dependence on third-party payor reimbursement, competition, and the ability to scale manufacturing. The filing notes that new federal tax legislation enacted in July 2025 did not have a material impact due to the company's full valuation allowance on deferred tax assets.
- Unusual Items: The Q3 results included a $3.7 million non-cash compensation expense and $0.7 million cash severance related to the former CEO's retirement.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with the amended loan facility covenants, specifically the minimum unrestricted cash or revenue/growth requirements if cash balances fall below $100 million.
- Reimbursement Status: Monitor updates on commercial payor coverage decisions outside of Medicare, as this is a primary driver for hospital adoption.
- Install Base Utilization: Track the rate of system utilization (procedures per system) to validate the recurring revenue model from handpiece sales.
- CEO Transition: Assess the impact of the leadership change on strategic execution and future SG&A expense trends.
- Cash Burn Rate: Review the trajectory of operating cash burn against the $294.3 million cash balance to confirm the 12-month runway estimate.